1. A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. (2021) Authors: Baik, Christina; Lee, Sylvia; Cook, Kitty; Wallace, Sarah; Wood, Rebecca; Santana-Davila, Rafael; Chow, Laura; Rodriguez, Cristina; Eaton, Keith D.; Martins, Renato Journal: Cancer treatment and research communications Issue: Number 28(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗